Bind Biosciences

TECHNOLOGY
Technology Medicinal Nanoengineering Platform Publications

Medicinal Nanoengineering® Platform

We create Accurins using a proprietary Medicinal Nanoengineering® platform that enables predictable, rapid design and optimization of targeted therapeutics with precisely controlled pharmacokinetic and biodistribution properties. We apply this platform to develop highly selective targeted therapeutics with unprecedented efficacy and tolerability.

The Medicinal Nanoengineering platform has demonstrated proof of concept across a broad range of drug classes and therapeutic areas. Preclinical studies validate the ability of our technology to improve the therapeutic index of cytotoxic agents, molecularly targeted anticancer drugs, and therapies for treating inflammation and pain.

How We Develop AccurinsTM

The Medicinal Nanoengineering platform uses a combinatorial approach to design and engineer nanoparticles with optimal targeting and drug-release properties, and subsequent production of materials for drug development and commercialization:

  • We design combinatorial libraries of targeted nanoparticles with precise and systematically varied biophysicochemical properties such as particle size, surface properties, ligand density, drug load, and drug release profile, using a unique self-assembly nanoparticle fabrication process to optimize each product-for example, to balance circulation time with effective targeting and binding for a particular cell or tissue target.
  • We engineer product candidates with optimal performance properties using an iterative process that includes in vitro drug release and cell binding as along with in vivo PK, tolerability, biodistribution, targeting, and efficacy studies.
  • We manufacture candidate Accurins from gram-scale laboratory experiments through kilogram-scale GMP clinical batches using robust, reproducible, and scalable processes.

Accurin Targeting

Our technology incorporates a therapeutic payload into a nanoparticle and achieves targeting through a dual mechanism:
  1. Passive/Biophysical Targeting: We engineer biophysical properties of the nanoparticles to avoid immune surveillance and fit through gaps in blood vessels surrounding tumors and other disease sites

  2. Active/Ligand-Directed, Receptor-Mediated Binding: We attach a targeting ligand on the surface of the nanoparticle to bind to specific cell-surface markers.